Page last updated: 2024-09-05

sorafenib and gdc 0941

sorafenib has been researched along with gdc 0941 in 10 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(gdc 0941)
Trials
(gdc 0941)
Recent Studies (post-2010) (gdc 0941)
6,5207305,25161056

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)gdc 0941 (IC50)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformRattus norvegicus (Norway rat)0.052
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)0.0553
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alphaHomo sapiens (human)6.039
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)0.3219
High affinity nerve growth factor receptorHomo sapiens (human)2.85
Cytochrome P450 3A4Homo sapiens (human)0.0033
Cholesteryl ester transfer proteinHomo sapiens (human)0.032
Phosphatidylinositol 3-kinase regulatory subunit alphaHomo sapiens (human)0.0737
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)0.037
AcetylcholinesteraseRattus norvegicus (Norway rat)0.003
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)0.0415
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)0.1086
Serine/threonine-protein kinase mTORHomo sapiens (human)0.7449
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)0.1626
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)1.23
Phosphatidylinositol 3-kinase catalytic subunit type 3Homo sapiens (human)0.4534
Phosphoinositide 3-kinase regulatory subunit 5Homo sapiens (human)0.117
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformRattus norvegicus (Norway rat)0.146

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (80.00)24.3611
2020's2 (20.00)2.80

Authors

AuthorsStudies
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Gong, P; Lin, H; Liu, Z; Wang, L; Wang, Y; Zhao, Y; Zuo, D1
Gong, P; Li, R; Liu, Z; Wang, J; Wang, L; Wang, Y; Wu, S; Zhao, Y1
Chen, C; Lei, F; OuYang, Y; Sun, C; Wang, L; Wang, Q; Xia, H; Xu, S; Zheng, P; Zhu, W1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Chen, D; Goh, WH; Soh, CK; Wang, H1
Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM1
Laufer, S; Pillaiyar, T1

Reviews

2 review(s) available for sorafenib and gdc 0941

ArticleYear
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
    European journal of medicinal chemistry, 2021, Jan-01, Volume: 209

    Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors

2021
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication

2022

Other Studies

8 other study(ies) available for sorafenib and gdc 0941

ArticleYear
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives containing diaryl urea moiety as potent antitumor agents.
    European journal of medicinal chemistry, 2014, Oct-06, Volume: 85

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Design; Drug Screening Assays, Antitumor; Humans; Pyrimidines; Structure-Activity Relationship; Urea

2014
Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents.
    European journal of medicinal chemistry, 2014, Nov-24, Volume: 87

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Magnetic Resonance Spectroscopy; Pyrimidines; Semicarbazones; Structure-Activity Relationship

2014
Design, synthesis, biological evaluation and docking studies of novel 2-substituted-4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as dual PI3Kα/mTOR inhibitors.
    European journal of medicinal chemistry, 2016, Jun-30, Volume: 116

    Topics: Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Conformation; Pyrimidines; TOR Serine-Threonine Kinases

2016
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
    Journal of medicinal chemistry, 2018, 02-22, Volume: 61, Issue:4

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2018